NASDAQ OMX

Medgate Launches EHS Professional Edition for Mid-Market Organizations

Dela

Easy to use and ready to go, SaaS solution empowers organizations to centralize and streamline EHS processes to save time and money, engage employees, and improve program performance

Toronto, May 17, 2017 (GLOBE NEWSWIRE) -- Medgate Inc., the global leader in enterprise-grade, SaaS-based Environmental, Health, Safety, and Quality (EHSQ) risk and information management solutions has introduced a new packaged solution that brings powerful EHS process automation capabilities to meet the business and program needs of mid-market organizations. This new solution brings 32 years of industry best practices into a rapidly deployed SaaS platform that is easy to use and ready to go for companies whose complexity of operations warrant enterprise-grade software, but require a solution designed for smaller scale operations.

To compete in today's ever-changing regulatory environment, organizations can no longer rely on spreadsheets, legacy applications or point solutions, particularly when demands continue to increase on already-stretched EHS resources.

Beyond the benefits of automation and risk mitigation, effective EHS programs are a competitive advantage. Until now, organizations looking to move to an advanced EHS software solution have found that although highly functional, some enterprise systems were too complex and costly for their needs. On the other hand, mid-market software simply offered 'less for less' or promised low cost and simplicity only to push a large configuration and customization burden onto the user.

This unmet market need is now addressed with Medgate's EHS Professional Edition.

"Medgate has grown to be the leader in serving enterprise-scale clients, but we began to see a major gap in the market for serving EHS professionals in mid-market organizations," said Medgate Director of Product Management, John Easton. "With our true SaaS platform, purpose-built workflows and rapid deployment approach, we saw an opportunity to bring the power of Medgate to an entirely new market. We studied the competitive landscape and have further refined the offering to bring something very unique for this market in Medgate's EHS Professional Edition."

Available immediately, the solution provides Medgate best practice workflows out-of-the-box, with simplified configurability to meet unique business needs. The solution covers:




Together, this powerful functionality enables a range of benefits that drive significantly stronger organizational performance.

Automation of core EHS processes


  • Ensure compliance, using auto-generated reports for OSHA, RIDDOR and many more
  • Drive efficiency with powerful out-of-the-box workflows
  • Leverage Medgate's expertise with pre-built reports
  • Reflect the unique nature of your business with easily configurable forms and views
  • Track KPIs in real-time and gain insights to improve business performance


Significant Time and Money Savings


  • Get up and running quickly with our expert implementation team and proven methodology
  • Save time, reduce paperwork, and drive better performance
  • Take advantage of our cloud-based SaaS software to reduce server and backup costs
  • Host your EHS data securely at Medgate's data centers. Medgate is the only ISO 27001 certified EHS software vendor


Better Employee Engagement


  • Foster employee engagement with simplified access through the Medgate Portal
  • Ensure user adoption with simplified, intuitive design
  • Access anywhere, any time with mobile and offline functionality
  • Find out what's really happening on the shop floor with easy event reporting for all employees



About Medgate

Medgate leverages its cutting-edge SaaS-based technology and broad EHSQ risk management solution to partner with organizations around the world to effect meaningful change in the way environmental, health, safety, and quality is managed. Medgate stands by its customers as they attain performance goals, reduce EHSQ risks, enhance corporate productivity, and create a healthier workforce. The company has received many accolades for its strong employee culture and outstanding growth rate including recognition as one of Canada's Best Managed Companies, being named by Aon Hewitt as one of the Best Employers in Canada, and being awarded Best New Product of the Year by Environmental Protection.

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/6d87e051-995f-47ea-83e0-b0f1b9144f83

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/61d1c6ce-5688-4c33-94b7-54ac48b63a7c

Medgate Inc.
media@medgate.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medgate Inc. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste pressmeddelandena från NASDAQ OMX

XBiotech to Present at Cantor Fitzgerald's Global Healthcare Conference21.9.2017 14:00Pressmeddelande

AUSTIN, Texas, Sept.  21, 2017  (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that management will be presenting at Cantor Fitzgerald's Global Healthcare Conference taking place September 25-27 at the InterContinental New York Barclay Hotel in New York City. Mr. Benjamin Guzman, the Company's Senior Vice President of Corporate Strategy & Finance, will provide a corporate overview on Wednesday, September 27th at 2:50pm Eastern Time. About True Human(TM) Therapeutic Antibodies Unlike previous generations of antibody therapies, XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability. About XBiotech

At the 10th anniversary of the iPhone, Chairman of Pilatus Bank draws a stark comparison of the role technology has played in banking vs telecommunication21.9.2017 08:58Pressmeddelande

LONDON, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Ali Sadr, Chairman of Pilatus Bank, believes that banks have failed to capture the true essence of technology for improving quality of service, as well as lacking the vision necessary to capture customers' imaginations. Meanwhile, other industries have been revolutionized and continue to thrive by the same technology. America has in the last 10 years been forced to close 10,000 branches. Since 2008, Europe has lost close to 48,000 branches, which is more than 20% of its branch network. There is little doubt that branch banking is on the decline, and online banking is failing to provide a quality service.  As we mark the 10th anniversary of the iPhone, Ali Sadr, Chairman of Pilatus Bank, gives a sobering count of the current state of affairs in the use of technology among well established banks, and elaborates on a vision that has the potential to become the largest revolution the banking industry is yet to experience. Chairman Al

Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA21.9.2017 08:00Pressmeddelande

Pressmeddelande 21 september 2017 Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA Immunicum AB (publ; First North Premier: IMMU.ST), ett bioteknikbolag som utvecklar nya immunostimulerande cancerbehandlingar för ett antal solida tumörer, meddelar idag att Society for Immunotherapy of Cancer (SITC) har accepterat att ett abstract kring ilixadencels verkningsmekanism presenteras som poster vid SITCs 32:a årsmöte som hålls 8-12 november, 2017 i Gaylord National Hotel & Convention Center i National Harbor, Maryland. Postern med titeln "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" presenteras av Immunicums forskningschef Alex Karlsson-Parra. Immunicum kommer att offentliggöra fullständiga data i ett pressmeddelande efter presentationen. När datum och tidpunkt för presentationen offentliggjorts kommer detta att fi

Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US21.9.2017 08:00Pressmeddelande

Press Release 21 September 2017 Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that the Society for Immunotherapy of Cancer (SITC) has accepted an abstract on ilixadencel's mode of action for a poster presentation at the SITC 32 nd Annual Meeting, held November 8-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland. The poster titled "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" will be presented by Immunicum's Chief Scientific Officer, Alex Karlsson-Parra. Immunicum will announce the complete data through a press relea

Asure Software to Attend at Quora Consulting's Smartworking Summit21.9.2017 07:00Pressmeddelande

Asure Join's Industry Leaders to Discuss "Understanding the Productivity Enigma" AUSTIN, Texas, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Asure Software, (NASDAQ:ASUR), a leading provider in human capital management and workspace management software, will be sponsoring Quora Consulting's Smartworking Summit in central London, September 28th 2017. These summits have continued to lead in addressing work space issues, such as occupancy, utilization, and productivity in the workforce. Dominic Jackson, Asure Sales Director of EMEA commented, "It is workplace issues like productivity that have driven thought leadership here at Asure." He continued "Utilization of workspace solutions help you recruit and retain the best talent, improve employee productivity, streamline operations, and realize a significant ROI on your most valuable assets - people, space and technology. We are thrilled to be not only part of the discussion, but part of the solu

Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure21.9.2017 00:23Pressmeddelande

DANVERS, Mass., Sept.  20, 2017  (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced it has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP® heart pump. Culminating from five years of research, this approval follows the prior FDA Humanitarian Device Exemption (HDE) received in January 2015 and adds the Impella RP heart pump to Abiomed's platform of PMA approved devices. With this approval, the Impella RP heart pump is the only percutaneous temporary ventricular support device that is FDA-approved as safe and effective for right heart failure as stated in the indication: The Impella RP System is indicated for providing temporary right ventricular support for up to 14 days in patients with a body surface area greater than or equal to 1.5 m2, who develop acute right heart failure or decompensation following left ventricular assist device impl

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum